Pioneering cancer medicine by harnessing metabolism in the DNA damage response
One-carbon Therapeutics AB is a clinical-stage biotechnology company pioneering novel anti-cancer therapies. Based on the strong preclinical data for TH9619 – first-in-class, potent, small molecule and dual inhibitor of MTHFD1/2 – One-carbon Therapeutics is targeting difficult to treat advanced refractory solid tumors. The company is headquartered in Sweden and is committed to translating cutting-edge metabolic science into transformative clinical impact for subjects worldwide.
TH9619 is a first-in-class, potent, small-molecule, and dual inhibitor of MTHFD1/2, highly overexpressed and cancer-specific enzymes within the one-carbon metabolic pathway. TH9619 kills cancer cells via a dual mechanism of action (1) inhibition of MTHFD1 traps folate leading to thymidine depletion (2) inhibition of nuclear MTHFD2 disrupts DNA damage response and repair pathways. With its unique characteristics, TH9619 kills tumor cells while sparing healthy tissue.
Background and Science
Cancer cells alter their metabolic pathways to meet the increased demand for energy and building blocks needed for rapid cell proliferation and survival. Yet, these alterations come with a cost of increased DNA damage that, if left unrepaired, will lead to cancer cell death. For this reason, cancer cells rely heavily on DNA damage response pathways to maintain genome integrity. Targeting these pathways is a common approach to treating cancer.
More recently, compelling findings indicate a connection between cancer metabolism and DNA damage repair processes. Metabolic enzymes represent a crucial group of factors within the DNA damage repair, opening novel ways to target these cancer vulnerabilities therapeutically.
Solna, Sweden, March 17h, 2026. One-carbon Therapeutics, a clinical-stage oncology company pioneering first-in-class targeted therapies based on deep understanding into cancer biology, today announced a
Solna, Sweden, December 1, 2025. One-carbon Therapeutics AB, a clinical-stage biotechnology company pioneering first-in-class cancer therapies, announced today the closing of an oversubscribed 153 million